Short-term effects and safety of an acute increase of intraocular pressure after intravitreal bevacizumab injection on corneal endothelial cells

Table 6 Characteristics of Endothelial Cells and IOP in Patients of phakic eyes Undergoing Intravitreal Bevacizumab Injection (mean ± SD)

	Baseline (n = 37)	After 2 min	After 5 min	After 30 min
IOP(mmHg)^a	11.57 ± 2.27	50.19 ± 10.68	38.35 ± 11.66	14.97 ± 5.00
CD(cells/mm²)^a	2673.41 ± 370.58	2673.88 ± 333.57	2656.46 ± 293.05	2674.32 ± 247.79
CV^a	64.05 ± 31.80	89.38 ± 78.67	75.51 ± 32.09	76.54 ± 37.58
6A(%)^a	40.30 ± 10.29	37.16 ± 15.45	38.76 ± 9.78	38.54 ± 11.85
CCT(μm)^a	510.21 ± 34.78	505.88 ± 29.56	505.76 ± 31.54	516.00 ± 29.35

After after injection, IOP intraocular pressure, CD corneal density, CV coefficient of variation, 6A hexagonality, CCT central corneal thickness; Baseline: before injection
^aIOP significant increased in a stepwise manner (all, p < 0.01). After 30 min, it normalized but still higher than baseline (p < 0.01). But there were no significant change in CD, CV, 6A, or CCT according to IOP over time than baseline (all, p > 0.05) by one-way repeated measures ANOVA, Bonferroni correction

ISSN: 1471-2415